North America Iron-Deficiency Anemia Therapy Market, By Therapy (Parenteral Iron Therapy and Oral Iron Therapy), Therapy Areas (Inflammatory Bowel Disease, Renal, Obstetrics and Gynecology, Congestive Heart Failure (CHF), Oncology and Others) Population (Adults, Pediatric and Geriatric), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
North America Iron-Deficiency Anemia Therapy Market Analysis and Size
Anemia is one of the most prevalent blood disorders in the current times. Intravenous iron drugs are facing much use due to their improved quality of treatment outside the dialysis, rising the number of dialysis patients, increasing number of diabetic patients in North America and increasing aging population. The number of research that aids the use of oral iron therapy as a substitute to intravenous treatments in hospital settings is also projected to increase the adoption of oral iron therapy among the population.
Data Bridge Market Research analyses a growth rate in the iron-deficiency anemia therapy market in the forecast period 2023-2030. The expected CAGR of iron-deficiency anemia therapy market is tend to be around 18.2% in the mentioned forecast period. The market was valued at USD 38,061.15 million in 2022, and it would grow upto USD 1,45,017.9 million by 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
North America Iron-Deficiency Anemia Therapy Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Therapy (Parenteral Iron Therapy and Oral Iron Therapy), Therapy Areas (Inflammatory Bowel Disease, Renal, Obstetrics and Gynecology, Congestive Heart Failure (CHF), Oncology and Others) Population (Adults, Pediatric and Geriatric), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Turkey, Belgium
|
|
Market Players Covered
|
Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Hikma Pharmaceuticals PLC (U.K.), Covis Pharma GmbH (U.S.), PHARMACOSMOS A/S (Denmark), Vifor Pharma Management Ltd. (Switzerland), Orion Corporation (Finland), PHARMACOSMOS A/S (Denmark), Shield Therapeutics (U.K.), Advanz Pharmaceutical (U.K.), Alkem Labs (India)
|
|
Market Opportunities
|
|
Market Definition
Iron deficiency anemia is a type of anemia that occurs when the body's iron stores are reduced. An inadequacy of healthy red blood cells specifies anemia. RBCs supply oxygen to human tissues. Iron is important in the production of haemoglobin. Haemoglobin deficiency shows lack of oxygen in the body. It's essential to keep your iron levels in check. Iron-rich foods such as meat, vegetables, fruits, and cereals can help treat or prevent iron deficiency. Vitamin C can help to prevent iron deficiency.
North America Iron-Deficiency Anemia Therapy Market Dynamics
Drivers
- Increasing Prevalence of Chronic Kidney Disease
As per the statistics of National Kidney Foundation, Inc., the two main causes of chronic kidney disease are diabetes and hypertension. More than 1 in 7, as in approximately 15% of U.S. adults or 37 million people, are projected to have CKD. Around 434.3 million people have CKD across the varied regions of North America, with most of the disease burden witnessed in China and India (up to 299.9 million). It is anticipated that the prevalence of chronic kidney cases will rise across highly economic countries, such as the U.S., which infers an increase in the aged population over the upcoming years.
- Growing Research and Clinical Activities
The rising number of research that supports the use of oral iron therapy as a substitute to intravenous treatments in hospital settings is anticipated to increase the adoption of oral iron therapy, thus increasing the segment growth. For instance, as per the latest study published by the IRESPUB Journal of Life Sciences, in January 2022, named "Oral iron formulae for treatment of iron deficiency anemia: a comparative study", oral iron supplementation has been considered the main solution for the treatment of iron deficiency anemia in children that impact their growth and development. Thus, this boosts the growth of the market.
Opportunities
- Increase in Anaemia
The increasing prevalence of iron deficiency anemia because of lack of sufficient iron quantities in food and excessive loss of red blood cells, particularly in women and children can lead to developmental defects in fetal problems in pregnant women and growing children, respectively. It has been observed that about 53% of the women were found to be anemic in 2020. According to the records of the National Heart, Lung, and Blood Institute, an expected 3 million individuals suffer from anaemia in North America. Increasing occurrence of target diseases, such as autoimmune diseases, rheumatoid arthritis, kidney conditions, liver disorders, cancer, thyroid diseases, and inflammatory bowel diseases, is a primary factor helping in the growth of the market for intravenous iron. Thus, it creates opportunity for the market growth.
- Increasing Incidence of Cancer
A rising number of cancer patients tend to develop iron deficiency anemia. Common types of cancer that are widely associated with anemia includes bone cancer, cervical cancer, blood cancer, colon cancer, and prostate cancer. Lung and breast tumors have been specified with the highest prevalence of anemia among solid tumors. Hematologic malignancies such as lymphoma, leukemia, and multiple myeloma produce abnormal blood cells that as a result harm the immune system and cause anemia. Cancer treatments such as chemotherapy and radiation therapy also increase anemia in cancer patients. This creates more opportunity in the market.
Restraints/Challenges
- Serious Effects of Iron Supplements
There are few serious effects that are associated with the intake of iron drugs. Common effects include digestive problems such as loss of appetite, nausea, stomach aches, constipation, and vomiting. The overdose of these drugs may also cause tiredness or weakness, shallow or rapid breathing, fatigue, bluish skin, convulsions, pale skin or fingernails. Thus, this impedes the market growth.
This North America iron-deficiency anemia therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the North America iron-deficiency anemia therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on North America Iron-Deficiency Anemia Therapy Market
The COVID-19 outbreak has disturbed the manufacturing and supply of intravenous iron drugs, however, increased initiatives by manufacturers and government to meet the demand has aided the growth of the market for intravenous iron drugs. In addition to this, numerous studies have recommended that Covid-19 infection has a huge risk of Acute Kidney Injury (AKI) and CKD, which, in turn, has fuelled the demand for intravenous iron drugs to treat CKD-related anemia. Health authorities advised that COVID-19 patients who had an acute kidney injury should be tested often as their risk of developing CKD is higher than others. Thus, COVID-19 had a major impact on the market growth.
North America Iron-Deficiency Anemia Therapy Market Scope
The North America iron-deficiency anemia therapy market is segmented on the basis of therapy, therapy areas, population, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Therapy
- Parenteral Iron Therapy
- Oral Iron Therapy
Therapy Areas
- Inflammatory Bowel Disease
- Renal
- Obstetrics and Gynecology
- Congestive Heart Failure (CHF)
- Oncology
- Others
Population
- Adults
- Pediatric
- Geriatric
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Iron-Deficiency Anemia Therapy Market Regional Analysis/Insights
The North America iron-deficiency anemia therapy market is analyzed and market size insights and trends are provided by therapy, therapy areas, population, distribution channel and end-user as referenced above.
The major countries covered in the North America iron-deficiency anemia therapy market report are U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Turkey, Belgium.
Germany is leading the market because of the quality and management of health care system, and growing research and development activities of anemia drugs among scientists. Also, the growing product approvals associated with iron deficiency anemia therapy and increasing company focus on developing effective therapy are anticipated to drive the market growth in the region during the forecast period.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Iron-Deficiency Anemia Therapy Market Share Analysis
The North America iron-deficiency anemia therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to North America iron-deficiency anemia therapy market.
Key players operating in the North America iron-deficiency anemia therapy market include:
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Covis Pharma GmbH (U.S.)
- PHARMACOSMOS A/S (Denmark)
- Vifor Pharma Management Ltd. (Switzerland)
- Orion Corporation (Finland)
- Shield Therapeutics (U.K.)
- Advanz Pharmaceutical (U.K.)
- Alkem Labs (India)
SKU-